STALICLA SA
Tuesday, June 04, 2024
CNS/Neurological
Company Presentation Theater 3
Stalicla, a global biotech firm, specializes in advancing precision medicine for brain diseases. Since 2017, it has raised $75M in private capital, with key shareholders including Novartis, Pictet, Edmond de Rothschild, and SPRIM. Stalicla's neuro precision platform, DEPI, focuses on Autism Spectrum Disorder, with two assets, STP1 and STP2, entering Phase 2. Additionally, STP7, licensed from Novartis, is in Phase III trials for substance use disorders, offering opportunities in the wider CNS field. STALICLA is preparing a $75M Series C to support Phase 2 trials, develop STP7, and expand its pipeline, with $24M secured for a new Phase II asset.
Company Website:
https://stalicla.com
Lead Product in Development:
STP7 (mavoglurant, in licensed from Novartis): a mGluR5 negative allosteric modulator platform with strong potential for neuropsychiatric disorders and other CNS indications. First indication for STP7 includes cocaine and alcohol use disorder and it is being advanced with the partnership of the NIH with a cocaine use disorder Phase 3 in 2025.
Company HQ City
Geneva
Company HQ State
Geneve
Company HQ Country
Switzerland
CEO/Top Company Official
Lynn Durham CEO & Founder
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())